Transcatheter aortic valve implantation for degenerative aortic valve regurgitation long after heart transplantation

Davide Zanuttini; Ilaria Armellini; Teodoro Bisceglia; Leonardo Spedicato; Guglielmo Bernardi; Rodolfo Muzzi; Alessandro Proclemer; Ugolino Livi

doi:10.1016/j.athoracsur.2013.03.040

Transcatheter aortic valve implantation for degenerative aortic valve regurgitation long after heart transplantation

Ann Thorac Surg. 2013 Nov;96(5):1864-6. doi: 10.1016/j.athoracsur.2013.03.040.

Authors

Davide Zanuttini¹, Ilaria Armellini, Teodoro Bisceglia, Leonardo Spedicato, Guglielmo Bernardi, Rodolfo Muzzi, Alessandro Proclemer, Ugolino Livi

Affiliation

¹ Department of Cardiology, Santa Maria della Misericordia Hospital, Udine, Italy.

PMID: 24182478
DOI: 10.1016/j.athoracsur.2013.03.040

Abstract

Transcatheter aortic valve implantation (TAVI) has become a feasible therapeutic option for the management of high-risk patients with severe degenerative aortic stenosis. Recently it has been extended to high-risk patients with severe aortic regurgitation. Degenerative aortic valve disease is generally uncommon in heart transplant recipients. We report the case of a 75-year-old man in whom severe degenerative aortic regurgitation developed 14 years after heart transplantation (HTx). Because of multiple comorbidities and high surgical risk, TAVI was preferred. A 29-mm CoreValve prosthesis (Medtronic Inc, Minneapolis, MN) was successfully implanted using a transfemoral approach.

Keywords: 35.

Publication types

Case Reports

MeSH terms

Aged
Aortic Valve / surgery*
Aortic Valve Insufficiency / surgery*
Catheterization
Heart Transplantation*
Heart Valve Prosthesis Implantation / methods*
Humans
Male
Postoperative Complications / surgery*
Severity of Illness Index
Time Factors